Georgia's Online Cancer Information Center

Find A Clinical Trial

Study With Immunotherapy Combinations in Participants With Metastatic Non-Small Cell Lung Cancer

Status
Active
Cancer Type
Lung Cancer
Trial Phase
Phase II
Eligibility
18 Years and older, Male and Female
Study Type
Treatment
NCT ID
NCT05676931
Protocol IDs
EDGE-Lung (primary)
NCI-2023-09840
2022-502916-35-00
Study Sponsor
Gilead

Summary

The purpose of this study is to assess the objective response rate (ORR) of
immunotherapy-based combination therapy and to assess the safety and tolerability of
immunotherapy-based combination therapy.

Eligibility

  1. Histologically confirmed, documented diagnosis of Stage IV metastatic, NSCLC
  2. Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1
  3. At least one measurable target lesion per RECIST v1.1.
  4. Adequate organ and marrow function
  5. Participants must be willing to provide adequate tumor tissue

Treatment Sites in Georgia

City of Hope Atlanta


600 Celebrate Life Parkway
Newnan, GA 30265
770-400-6169
www.cityofhope.org/locations/atlanta/atlanta-cancer-center

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.